Venaxis, Inc. to Present at Biotech Showcase™ 2015

CASTLE ROCK, Colo., Jan. 6, 2015 /PRNewswire/ -- Venaxis®, Inc. APPY, an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1® Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will be presenting at the Biotech Showcase™ 2015, being held January 12-14, 2015, at the Parc 55 Wyndham Union Square Hotel in San Francisco, California. 

Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event: Biotech Showcase 2015
Presentation: Monday, January 12, 2015, 4:30 pm (Pacific Time)
Location: Parc 55 Wyndham Union Square Hotel; Track D (Powell)

About Venaxis, Inc. 
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid blood based test for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low probability for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent, and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, a limited commercial launch for the APPY1 Test is ongoing in select European countries. For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from our products at a profitable price point, successfully complete required product development and modifications of our next generation products in a timely and cost effective manner, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-K for the year ended December 31, 2013, filed with the SEC on March 28, 2014.

Venaxis and APPY1 are registered trademarks and APPYAnalytics is a trademark of Venaxis, Inc.

Contact – Jed Mahan, jmahan@venaxis.com; (303) 794-2000 ext. 255

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/venaxis-inc-to-present-at-biotech-showcase-2015-300016633.html

SOURCE Venaxis, Inc.